MARKET

DGNOF

DGNOF

Diagnos Inc
OTCMQB
0.150
-0.017
-10.02%
Opening 10:54 07/27 EDT
OPEN
0.150
PREV CLOSE
0.167
HIGH
0.150
LOW
0.150
VOLUME
7.01K
TURNOVER
1.05K
52 WEEK HIGH
0.288
52 WEEK LOW
0.133
MARKET CAP
18.16M
P/E (TTM)
-4.9505
1D
5D
1M
3M
1Y
5Y
1D
Diagnos seeks to extend expiry of 6,715,369 warrants to June 5, 2027
PUBT · 07/07 16:39
DIAGNOS to Extend the Exercise Period of Stock Warrants
Barchart · 07/07 11:38
Diagnos to settle C$125,000 debt with 625,000 shares at C$0.2 each
PUBT · 06/18 16:00
DIAGNOS Announces Shares for Debt Settlement
Barchart · 06/18 11:00
Diagnos submits updated Health Canada license application for CARA platform
PUBT · 06/16 13:16
DIAGNOS SUBMITS MODIFIED AND UPDATED HEALTH CANADA LICENCE APPLICATION FOR CARA SYSTEM PLATFORM
Reuters · 06/16 13:15
Diagnos targets June 10 Health Canada submission for next-generation CARA AI platform
PUBT · 06/05 14:12
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
Barchart · 06/05 09:00
More
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

Webull offers Diagnos Inc stock information, including OTCMQB: DGNOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGNOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGNOF stock methods without spending real money on the virtual paper trading platform.